CTC (Chicago Trading Company)’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-24,266
Closed -$1.01M – 230
2024
Q4
$1.01M Buy
24,266
+18,968
+358% +$907K ﹤0.01% 247
2024
Q3
$354K Sell
5,298
-1,042
-16% -$95.7K ﹤0.01% 270
2024
Q2
$753K Sell
6,340
-26,801
-81% -$3.39M ﹤0.01% 274
2024
Q1
$3.53M Buy
+33,141
New +$3.34M ﹤0.01% 262
2023
Q4
– Sell
-46,863
Closed -$3.94M – 328
2023
Q3
$4.84M Sell
46,863
-31,485
-40% -$3.51M ﹤0.01% 278
2023
Q2
$9.52M Buy
+78,348
New +$10.5M ﹤0.01% 245
2022
Q1
– Sell
-224
Closed -$37.7K – 302
2021
Q4
$56.9K Buy
224
+170
+315% +$49.7K 0.02% 96
2021
Q3
$20.8K Buy
+54
New +$19.9K 0.01% 117

Other funds holding MRNA

CTC (Chicago Trading Company)'s MRNA Position: Q1 2025 in Review

CTC (Chicago Trading Company) sold out of Moderna (MRNA) in Q1 2025, closing a stake of 24,266 shares — an estimated $1.01M sold.

CTC (Chicago Trading Company) first reported a position in MRNA in Q3 2021 and held it in 8 quarters. The position peaked at $9.52M in Q2 2023. 696 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • CTC (Chicago Trading Company) reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • CTC (Chicago Trading Company) sold 24,266 Moderna shares in Q1 2025, an estimated $1.01M.
  • CTC (Chicago Trading Company) first reported a position in Moderna in Q3 2021 and held it in 8 quarters.
  • CTC (Chicago Trading Company)'s Moderna position peaked at $9.52M in Q2 2023.
  • 696 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on CTC (Chicago Trading Company)'s 13F filing for Q1 2025, filed 16 May 2025.